Hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil, and oxaliplatin plus intravenous cetuximab (Cet) (Optiliv) after failure on one versus two or three chemotherapy protocols in patients (pts) with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) (European phase II clinical trial NCT00852228).

被引：0

作者：

Ducreux, Michel

Innominato, Pasquale F.

Hebbar, Mohamed

Smith, Denis Michel

Lepere, Celine

Focan, C. N. J.

Guimbaud, Rosine

Carvalho, Carlos

Tumolo, Salvatore

Awad, Sameh

Truant, Stephanie

Castaing, Denis

Karaboue, Abdoulaye

De Baere, Thierry

Kunstlinger, Francis

Bouchahda, Mohamed

Boige, Valerie

Rougier, Philippe

Adam, Rene

Levi, Francis

机构：

[1] Inst Gustave Roussy, Villejuif, France

[2] Hop Paul Brousse, INSERM, U776, Villejuif, France

[3] Ctr Hosp Reg & Univ Lille, Hop Huriez, Med Oncol Unit, F-59037 Lille, France

[4] Hop St Andre, Bordeaux, France

[5] Hop Europeen Georges Pompidou, Paris, France

[6] CHC Clin St Joseph, Liege, Belgium

[7] Univ Hosp Purpan, Toulouse, France

[8] Hosp Fernando Fonesca, Med Oncol Unit, Amadora, Portugal

[9] S Maria degli Angeli Hosp, Dept Med Oncol, Pordenone, Italy

[10] Hop Paul Brousse, Dept Radiol, Villejuif, France

[11] CHU Lille, F-59037 Lille, France

[12] Hop Paul Brousse, Hepatobiliary Ctr, Villejuif, France

[13] Hop Paul Brousse, Ctr Hepatobilliaire, Villejuif, France

[14] Hop Paul Brousse, INSERM, U776, Dept Med Oncol, Villejuif, France

[15] Inst Gustave Roussy, Serv Hepatogastroenterol, Villejuif, France

[16] European Hosp George Pompidou, Paris, France

[17] Hop Paul Brousse, Hepatobiliary Ctr, Villejuif, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3599

引用

页数：1

共 16 条

[1] Final results of first European phase II trial of intravenous cetuximab (Cet) and hepatic artery infusion of irinotecan, 5-fluorouracil, and oxaliplatin in patients (pts) with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) after systemic treatment failure (OPTILIV, NCT00852228).
Levi, Francis
Boige, Valerie
Hebbar, Mohamed
Smith, Denis
Lepere, Celine
Focan, C. N. J.
Guimbaud, Rosine
Carvalho, Carlos
Tumolo, Salvatore
Innominato, Pasquale F.
Ajavon, Yves
Truant, Stephanie
Castaing, Denis
De Baere, Thierry
Kunstlinger, Francis
Karaboue, Abdoulaye
Bouchahda, Mohamed
Rougier, Philippe R.
Adam, Rene
Ducreux, Michel
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
[2] First European phase II trial of intravenous (iv) cetuximab (Cet) and hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin in patients with unresectable liver metastases from wt KRAS colorectal cancer (CRC) after systemic therapy failure (OPTILIV, NCT00852228)
Levi, Francis
Ducreux, Michel
Hebbar, Mohamed
Rougier, Philippe
Focan, C. N. J.
Guimbaud, Rosine
Carvalho, Carlos
Tumolo, Salvatore
Innominato, Pasquale F.
Ajavon, Yves
Castaing, Denis
De Baere, Thierry
Karaboue, Abdoulaye
Lepere, Celine
Boige, Valerie
Proux, Laetitia
Adam, Rene
Bouchahda, Mohamed
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[3] Chronomodulated hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil (5-FU), and oxaliplatin (l-OHP) plus intravenous (iv) cetuximab (Cet) (Chrono-Optiliv) in patients with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) after treatment failure (European Phase II trial NCT 00852228)
Bouchahda, Mohamed
Karaboue, Abdoulaye
Etienne-Grimaldi, Marie-Christine
Chatelut, Etienne
Innominato, Pasquale F.
Paintaud, Gilles
Ricca, Luana
Vibert, Eric
Ajavon, Yves
Awad, Sameh
Castaing, Denis
Focan, C. N. J.
Milano, Gerard
Morere, Jean Francois
Adam, Rene
Levi, Francis
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[4] Early tumor shrinkage as a predictor for long-term outcome in patients (pts) with unresectable liver metastases from wt-KRAS colorectal cancer (LM-CRC) treated with hepatic artery infusion (HAI) of Irinotecan, 5-Fluorouracil and Oxaliplatin plus intravenous Cetuximab (IV-Cet) after failure of one to three systemic protocols (European phase II clinical trial NCT00852228)
Bouchahda, M.
Michel, D.
Denis, S.
Abdoulaye, K.
Mohamed, H.
Celine, L.
Christian, F.
Rosine, G.
Pasquale, I.
Sameh, A.
Carlos, C.
Salvatore, T.
Stephanie, T.
Thierry, D. B.
Denis, C.
Philippe, R.
Valerie, B.
Francois, M. Jean
Rene, A.
Francis, L.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S348 - S348
[5] SAFETY AND EFFICACY OF INTRAVENOUS CETUXIMAB (CET) AND HEPATIC ARTERY INFUSION OF IRINOTECAN, 5-FLUOROURACIL AND OXALIPLATIN IN PATIENTS WITH UNRESECTABLE LIVER METASTASES FROM WT KRAS COLORECTAL CANCER (CRC): RESULTS FROM OPTILIV EUROPEAN PHASE II TRIAL
Levi, F.
Boige, V.
Rougier, P.
Hebbar, M.
Smith, D.
Focan, C.
Guimbaud, R.
Carvalho, C.
Bouchahda, M.
Ducreux, M.
ANNALS OF ONCOLOGY, 2012, 23 : 194 - 194
[6] Four-year survival in patients (pts) undergoing liver surgery after neoadjuvant triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) for previously treated and unresectable liver metastases from kras wt colorectal cancer (LM-CRC) (European trial OPTILIV, NCT00852228).
Levi, Francis
Ducreux, Michel
Smith, Denis Michel
Hebbar, Mohamed
Lepere, Celine
Focan, C. N. J.
Guimbaud, Rosine
Innominato, Pasquale F.
Carvalho, Carlos
Tumolo, Salvatore
Truant, Stephanie
Castaing, Denis
Karaboue, Abdoulaye
Boige, Valerie
Bouchahda, Mohamed
Rougier, Philippe
Adam, Rene
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[7] Robustness of circadian rest-activity rhythm for predicting efficacy of intravenous cetuximab (Cet) and hepatic artery infusion (HAI) of chronomodulated irinotecan, 5-fluorouracil and oxaliplatin (Chrono-Optiliv) for liver metastases from colorectal cancer (LM-CRC) (Optiliv translational study, NCT00852228).
Karaboue, Abdoulaye
Innominato, Pasquale F.
Bouchahda, Mohamed
Mocquery, Magali
Bossevot, Rachel
Plessis, Virginie
Bouchoucha, Davina
Adam, Rene
Levi, Francis
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[8] Impact of early tumor response on prognostic of patients with unresectable liver metastases from wt-KRAS colorectal cancer (LM-CRC) treated with hepatic artery infusion of irinotecan, 5-fluorouracil and oxaliplatin plus intravenous cetuximab after failure of systemic chemotherapy (European Phase II OPTILIV)
Bouchanda, Mohamed
Boige, Valerie
Smith, Denis Michel
Karaboua, Abdoulaye
Hebbar, Mohamed
Lepere, Celine
Focan, C. N. J.
Guimbaud, Rosine
Innominato, Pasquale F.
Awad, Sameh
Carvalho, Carlos
Tumolo, Salvatore
Truant, Stephanie
De Baere, Thierry
Castaing, Denis
Rougier, Philippe
Taieb, Julien
Morere, Jean F.
Ducreux, Michel
Levi, Francis
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[9] Constitutive single nucleotide polymorphisms (SNP) assessment for predicting tolerability and efficacy of triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) in patients (pts) with liver metastases from colorectal cancer (LM-CRC) (European trial OPTILIV, NCT00852228).
Levi, Francis
Karaboue, Abdoulaye
Saffroy, Raphael
Peyric, Elodie
Ducreux, Michel
Smith, Denis Michel
Hebbar, Mohamed
Innominato, Pasquale F.
Pernot, Simon
Carvalho, Carlos
Guimbaud, Rosine
Focan, C. N. J.
Bouchahda, Mohamed
Adam, Rene
Etienne-Grimaldi, Marie-Christine
Milano, Gerard A.
Lemoine, Antoinette
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[10] Safety and efficacy of neoadjuvant combination of hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil, and oxaliplatin with intravenous (iv) cetuximab in patients with unresectable liver metastases from colorectal cancer (CRC): Interim report from OPTILIV-A European multicenter phase II trial.
Ducreux, M.
Rougier, P.
Smith, D.
Focan, C. N. J.
Innominato, P. F.
Bouchahda, M.
Ajavon, Y.
Castaing, D.
De Baere, T.
Karaboue, A.
Lepere, C.
Boige, V.
Adam, R.
Levi, F.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

← 1 2 →